ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2022
[Expert opinion on expanding anti-HBV treatment for chronic hepatitis B].
Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05937178 (A Real-world Study of Optimizing Nucleotide-analogues-based Treatment for Chronic Hepatitis B), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Real-world Study of Optimizing Nucleotide-analogues-based Treatment for Chronic Hepatitis B
Who cites it
24 citing papers in PubMed.
- Chronic liver disease questionnaire analysis in pregnant women with hepatitis B: a prospective study.BMC pregnancy and childbirth · 2026Article
- Low HBV replication does not aggravate disease progression in patients with superinfection with HEV.Scientific reports · 2025Article
- Impact of Alanine Transaminase Thresholds on Treatment Eligibility of Patients with Chronic Hepatitis B: A Cross-sectional Study of the China Registry of Hepatitis B.Journal of clinical and translational hepatology · 2025Article
- Chronic hepatitis B: Is it time for expanded antiviral treatment?World journal of virology · 2025Review
- Article
- Assessment of the risk of discontinuation of tenofovir disoproxil fumarate after delivery and the benefit of continued treatment in patients with immune tolerance.Frontiers in medicine · 2025Article
- Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children.Infectious diseases & immunity · 2024Article
- "Treat-all" Strategy for Patients with Chronic Hepatitis B Virus Infection in China: Are We There Yet?Journal of clinical and translational hepatology · 2024Review
- Latest insights into the epidemiology, characteristics, and therapeutic strategies of chronic hepatitis B patients in indeterminate phase.European journal of medical research · 2024Review
- Detection technology and clinical applications of serum viral products of hepatitis B virus infection.Frontiers in cellular and infection microbiology · 2024Review
- High immunocompetence in chronic hepatitis patients with normal alanine transaminase levels and and negative hepatitis B e-antigen for the progression of liver fibrosis.Immunity, inflammation and disease · 2024Article
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis.Frontiers in medicine · 2024Review
- Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022).Journal of clinical and translational hepatology · 2023Article
- Tenofovir amibufenamideWorld journal of gastroenterology · 2023Article
- Lowering the threshold of alanine aminotransferase for enhanced identification of significant hepatic injury in chronic hepatitis B patients.World journal of gastroenterology · 2023Article
- Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation.The Lancet regional health. Western Pacific · 2023Article
- Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Article
- Hepatic and portal vein Doppler ultrasounds in assessing liver inflammation and fibrosis in chronic HBV infection with a normal ALT level.Frontiers in medicine · 2023Article
- The urgency to expand the antiviral indications of general chronic hepatitis B patients.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To meet the unmet medical needs and better reflect the new clinical evidence of chronic hepatitis B management, Chinese Society of Hepatology developed expert consensus on expanding diagnosis and treatment in China. The recommendations include to expand HBsAg screening in the population and HBV DNA detection by sensitive quantitative real-time PCR (qPCR), decrease the alanine aminotransferase (ALT) threshold for treatment of chronic hepatitis B, and promptly start antiviral therapy in the patients who are at risk of disease progression, and appropriately manage the patients with low level viremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.